Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 134 of the 134 references it cites were found in a registry or an index; 34 of the 56 sources its claims cite were checked for support.

Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia

Open access

Published version of a preprint

Abstract

Tolerance to antifungal drug concentrations above the minimal inhibitory concentration (MIC) is rarely quantified, and current clinical recommendations suggest it should be ignored. Here, we quantify antifungal tolerance in Candida albicans isolates as the fraction of growth above the MIC, and find that it is distinct from susceptibility/resistance. Instead, tolerance is due to the slow growth of subpopulations of cells that overcome drug stress more efficiently than the rest of the population, and correlates inversely with intracellular drug accumulation. Many adjuvant drugs used in combination with fluconazole, a widely used fungistatic drug, reduce tolerance without affecting resistance. Accordingly, in an invertebrate infection model, adjuvant combination therapy is more effective than fluconazole in treating infections with highly tolerant isolates and does not affect infections with low tolerance isolates. Furthermore, isolates recovered from immunocompetent patients with persistent candidemia display higher tolerance than isolates readily cleared by fluconazole. Thus, tolerance correlates with, and may help predict, patient responses to fluconazole therapy.

Overview

CoChat Summary

TL;DR

Antifungal tolerance in *Candida albicans*, quantified as fraction of growth above the MIC (FoG) or supra-MIC growth (SMG), is a stable subpopulation phenotype distinct from resistance and inversely correlates with intracellular fluconazole accumulation. High tolerance is associated with persistent candidemia, and adjuvant combinations reduce tolerance and improve outcomes in a *Galleria mellonella* infection model for high-tolerance isolates.

Key findings

  • In 219 clinical *C. albicans* isolates, FoG ranged from 0.10 to 0.85 and did not correlate with the zone-of-inhibition radius RAD (R² < 0.01); FoG and SMG correlated with each other (R² = 0.82, P < 0.01), while FoG and RAD did not. Tolerance was concentration-independent, unlike RAD/MIC.
  • Tolerance reflected a growing subpopulation: CFUs on supra-MIC fluconazole ranged from 2% to 98% of the no-drug population and correlated with FoG (R² = 0.91, P < 0.01). High-FoG strains had shorter delay in colony appearance on drug and faster recovery, without being explained by faster drug-free growth.
  • Steady-state intracellular FLC-Cy5 at 24 h correlated inversely with FoG (R² = 0.8, P < 0.01); the proportion of cells with high FLC-Cy5 inversely correlated with FoG (R² = 0.82, P = 0.04), and mid FLC-Cy5 positively correlated (R² = 0.81, P = 0.05). R6G efflux did not correlate with FoG (R² < 0.2).
  • Adjuvants reduced FoG without altering RAD/MIC and rendered fluconazole cidal. In *G. mellonella*, FLC + fluphenazine rescued up to 50% of larvae infected with high-FoG strains, whereas high-FoG strains did not respond to FLC alone. Persistent candidemia isolates had higher FoG/SMG than non-persistent isolates, with many persistent isolates having FoG > 0.5, despite similar MICs (0.25–1 µg/ml).

Methods

  • Drug responses were quantified in *C. albicans* clinical isolates and lab strains using disk diffusion assays analyzed with diskImageR (RAD and FoG at 20% inhibition) and broth microdilution assays (MIC₅₀ at 24 h; SMG at 48 h). A screen included 219 clinical isolates; standard assays used a 25 µg FLC disk, 30 °C, and 48 h incubation.
  • Mechanistic assays included CFU plating, microcolony time-lapse microscopy, ScanLag colony-growth analysis, viability replica plating, growth-rate measurements, FLC-Cy5 uptake by flow cytometry, Rhodamine 6G efflux, Hsp90 ELISA, and mutant strain analysis.
  • In vivo testing used *Galleria mellonella* larvae infected with *C. albicans* and treated with PBS, FLC, or FLC + fluphenazine. Clinical isolates came from patients with candidemia either cleared by FLC (non-persistent) or persistent despite FLC therapy; statistical tests included t tests, ANOVA/Tukey, and log-rank tests.

Limitations

  • Stated in the paper: aneuploidy could contribute to tolerance in some strains, though the authors argue it is unlikely to be the main mechanism; factors other than uptake and efflux that determine intracellular FLC levels remain to be determined; how TOR, unfolded protein response, PKC signaling, sphingolipid synthesis, iron homeostasis, fluoxetine, and fluphenazine affect drug responses remains to be determined; causality between infection and death could not be determined; and for highly resistant strains such as T101, the small zone of inhibition makes FoG measurements less accurate than SMG.
  • Stated in the paper: previous work suggested trailing growth was not important for virulence or human infection outcomes, but those studies analyzed short-term responses rather than persistence/recurrence; the authors call for retrospective and prospective clinical studies measuring tolerance.
  • Evident from the text: the in vivo model is an invertebrate (*G. mellonella*) rather than a mammalian model; the clinical association is correlational with limited isolate sets (7 non-persistent isolates and 12 persistent series); and tolerance assays are sensitive to pH, temperature, and growth media, requiring consistent conditions for reproducibility.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04926-x

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Measuring drug responses in disk diffusion assays (DDAs) and in liquid broth microdilution assays (BMDAs). a diskImageR analysis measures pixel intensity corresponding to cell density, along 72 radii every 5°. The average radius (RAD) represents the distance in mm corresponding to the point where 20%, 50%, or 80% growth reduction occurs (light, medium, dark blue dots). The fraction of growth inside the zone of inhibition (FoG) is the area under the curve (red) at the RAD threshold, divided by the maximum area. b Range of FoG levels in 219 C. albicans clinical isolates. Red, blue, and green lines estimate high, medium, and low FoG levels, respectively. Unless otherwise specified, DDAs were performed using a single 25 µg FLC disk and analyzed after 48 h at 30 °C. c Comparison of FoG20 and RAD20 for the 219 isolates. d Illustration of MIC and supra-MIC growth (SMG) calculations. MIC50 was calculated at 24 h as the FLC concentration at which 50% of the growth was inhibited, relative to growth in the absence of drug. SMG was calculated as the average growth per well above the MIC divided by the level of growth without drug. FLC was used in two-fold dilutions (0, 0.125 to 128 μg/ml). e Heatmaps illustrating OD600 levels for concentrations below the MIC (yellow bar) in cyan and above the MIC in yellow for the isolates from Fig. 1c. Maps show OD600 values at 24 and 48 h. f, g Effect of incubation time on RAD/MIC and FoG/SMG values. diskImageR analysis (f) and corresponding MIC and SMG levels (g) measured at 24 and 48 h for strains as in d. Of note, for truly drug-resistant strains such as T101 (MIC = 64, e), the small zone of inhibition makes FoG measurements less accurate than SMG levels. h RAD is concentration-dependent and FoG is concentration-independent as illustrated for strain SC5314 exposed to disks containing increasing concentrations of FLC (25, 50 and 300 µg) (left); RAD (middle) and FoG (right) levels for strains as listed. For all panels, n ≥ 2; ** P < 0.01; *P < 0.05
Fig. 1 Measuring drug responses in disk diffusion assays (DDAs) and in liquid broth microdilution assays (BMDAs). a diskImageR analysis measures pixel intensity corresponding to cell density, along 72 radii every 5°. The average radius (RAD) represents the distance in mm corresponding to the point where 20%, 50%, or 80% growth reduction occurs (light, medium, dark blue dots). The fraction of growth inside the zone of inhibition (FoG) is the area under the curve (red) at the RAD threshold, divided by the maximum area. b Range of FoG levels in 219 C. albicans clinical isolates. Red, blue, and green lines estimate high, medium, and low FoG levels, respectively. Unless otherwise specified, DDAs were performed using a single 25 µg FLC disk and analyzed after 48 h at 30 °C. c Comparison of FoG20 and RAD20 for the 219 isolates. d Illustration of MIC and supra-MIC growth (SMG) calculations. MIC50 was calculated at 24 h as the FLC concentration at which 50% of the growth was inhibited, relative to growth in the absence of drug. SMG was calculated as the average growth per well above the MIC divided by the level of growth without drug. FLC was used in two-fold dilutions (0, 0.125 to 128 μg/ml). e Heatmaps illustrating OD600 levels for concentrations below the MIC (yellow bar) in cyan and above the MIC in yellow for the isolates from Fig. 1c. Maps show OD600 values at 24 and 48 h. f, g Effect of incubation time on RAD/MIC and FoG/SMG values. diskImageR analysis (f) and corresponding MIC and SMG levels (g) measured at 24 and 48 h for strains as in d. Of note, for truly drug-resistant strains such as T101 (MIC = 64, e), the small zone of inhibition makes FoG measurements less accurate than SMG levels. h RAD is concentration-dependent and FoG is concentration-independent as illustrated for strain SC5314 exposed to disks containing increasing concentrations of FLC (25, 50 and 300 µg) (left); RAD (middle) and FoG (right) levels for strains as listed. For all panels, n ≥ 2; ** P < 0.01; *P < 0.05CC BY · PubMed Central
Fig. 2 Analysis of cells growing at supra-MIC concentrations. All tested strains, except for T101 (MIC = 64 µg/ml), had FLC MIC values below 10 µg/ml. a FoG correlates with the proportion of colonies that grow on 10 µg/ml FLC relative to growth on plates without drug. Black dots are additional strains from Fig. 1c. b Microcolony analysis at supra-MIC concentrations of FLC (10 µg/ml). Symbols indicate cells that have stopped dividing in the presence of drug over 24 h, scale bars = 100 µm. On average, strain AM2 formed fewer microcolonies than strain SC5314, but these were larger than those formed by SC5314. Time-lapse videos are available as Supplementary Movies 1–4. c, d Growth rate analysis of cells growing at supra-MIC FLC (10 µg/ml) during 0–5 h (c) and 10–15 h (d). e Schematic of ScanLag analysis75 that measures time of colony appearance (ToA), colony growth rate, and colony size using desktop scanners. f ToA on medium without drug (blue) or with 10 µg/ml FLC (red) for resistant isolate T101, and isolates with different FoG levels. Graphs show the number of colonies (y-axis) at each time point (x-axis). Additional isolates are included in Supplementary Fig. 4. g Correlation between FoG20 and the difference (Δ) in the ToA of colonies in the presence vs. absence of FLC (ΔToA = ToA with FLC – ToA without FLC). Black dots are additional strains from Fig. 1c. h Cells that grow within the zone of inhibition are viable, as seen by replica plating of disk diffusion assays grown on casitone without FLC and incubated at 30 °C for 48 h. For all panels, n ≥ 2; ***P < 0.001; error bars denote standard deviations
Fig. 2 Analysis of cells growing at supra-MIC concentrations. All tested strains, except for T101 (MIC = 64 µg/ml), had FLC MIC values below 10 µg/ml. a FoG correlates with the proportion of colonies that grow on 10 µg/ml FLC relative to growth on plates without drug. Black dots are additional strains from Fig. 1c. b Microcolony analysis at supra-MIC concentrations of FLC (10 µg/ml). Symbols indicate cells that have stopped dividing in the presence of drug over 24 h, scale bars = 100 µm. On average, strain AM2 formed fewer microcolonies than strain SC5314, but these were larger than those formed by SC5314. Time-lapse videos are available as Supplementary Movies 1–4. c, d Growth rate analysis of cells growing at supra-MIC FLC (10 µg/ml) during 0–5 h (c) and 10–15 h (d). e Schematic of ScanLag analysis75 that measures time of colony appearance (ToA), colony growth rate, and colony size using desktop scanners. f ToA on medium without drug (blue) or with 10 µg/ml FLC (red) for resistant isolate T101, and isolates with different FoG levels. Graphs show the number of colonies (y-axis) at each time point (x-axis). Additional isolates are included in Supplementary Fig. 4. g Correlation between FoG20 and the difference (Δ) in the ToA of colonies in the presence vs. absence of FLC (ΔToA = ToA with FLC – ToA without FLC). Black dots are additional strains from Fig. 1c. h Cells that grow within the zone of inhibition are viable, as seen by replica plating of disk diffusion assays grown on casitone without FLC and incubated at 30 °C for 48 h. For all panels, n ≥ 2; ***P < 0.001; error bars denote standard deviationsCC BY · PubMed Central
Fig. 3 Uptake, efflux and steady-state intracellular concentrations of FLC-Cy5. a Average intracellular FLC-Cy5 uptake per cell. Uptake curves for 0–5 h and for steady-state FLC-Cy5 per cell at 24 h measured by flow cytometry. b, c Correlation between FoG20 and uptake rate of FLC-Cy5 between 0.5 and 1.5 h (b) and intracellular FLC-Cy5 at 24 h (c). d Intracellular FLC-Cy5 fluorescent intensity at 24 h for four strains with similar MIC and diverse FoG levels (left) and for the resistant strain T101 (right) normalized for number of cells (n = 15863 for P87, 15075 of P78, 22406 for SC5314, 18186 for GC75). e The proportion of cells (%) with FLC-Cy5 levels at 24 h was divided into thirds: Low (391–422 A.U.), Mid (3912–34,643 A.U.), and High (3.5 × 104–3.14 × 105 A.U.) (upper panel). Proportion of cells (%) with high (lower left panel) or mid (lower right panel) intracellular FLC-Cy5 concentration at 24 h vs. FoG20 levels of the strains. f Efflux of Rhodamine 6G (R6G) normalized by culture density (OD600). Efflux curves represent data from one (of two) experiment and the curves show fluorescence intensity recorded over 90 min and calculated as follows: Δ[FLC(with glucose − without glucose) − no drug(with glucose − without glucose)]. g Cartoon illustrates the steady-state drug levels in cells with high to low FoG levels. For all panels, n ≥ 2; **P < 0.01; *P < 0.05, error bars denote standard deviations
Fig. 3 Uptake, efflux and steady-state intracellular concentrations of FLC-Cy5. a Average intracellular FLC-Cy5 uptake per cell. Uptake curves for 0–5 h and for steady-state FLC-Cy5 per cell at 24 h measured by flow cytometry. b, c Correlation between FoG20 and uptake rate of FLC-Cy5 between 0.5 and 1.5 h (b) and intracellular FLC-Cy5 at 24 h (c). d Intracellular FLC-Cy5 fluorescent intensity at 24 h for four strains with similar MIC and diverse FoG levels (left) and for the resistant strain T101 (right) normalized for number of cells (n = 15863 for P87, 15075 of P78, 22406 for SC5314, 18186 for GC75). e The proportion of cells (%) with FLC-Cy5 levels at 24 h was divided into thirds: Low (391–422 A.U.), Mid (3912–34,643 A.U.), and High (3.5 × 104–3.14 × 105 A.U.) (upper panel). Proportion of cells (%) with high (lower left panel) or mid (lower right panel) intracellular FLC-Cy5 concentration at 24 h vs. FoG20 levels of the strains. f Efflux of Rhodamine 6G (R6G) normalized by culture density (OD600). Efflux curves represent data from one (of two) experiment and the curves show fluorescence intensity recorded over 90 min and calculated as follows: Δ[FLC(with glucose − without glucose) − no drug(with glucose − without glucose)]. g Cartoon illustrates the steady-state drug levels in cells with high to low FoG levels. For all panels, n ≥ 2; **P < 0.01; *P < 0.05, error bars denote standard deviationsCC BY · PubMed Central
Fig. 4 Adjuvant drugs significantly reduce FLC tolerance but not resistance and render FLC cidal. a Disk diffusion assays performed with 25 µg FLC on casitone plates supplemented with adjuvant drugs 20 µg/ml fluoxetine, 5 ng/ml aureobasidin A, 0.5 ng/ml rapamycin, 10 µg/ml fluphenazine, 12.5 ng/ml staurosporine, 0.25 µg/ml tunicamycin, Hsp90 inhibitors (0.5 µg/ml geldanamycin and 0.5 µg/ml radicicol), and calcineurin inhibitors (0.5 µg/ml FK506 and 0.4 µg/ml cyclosporine A) shown for strain SC5314. b RAD and FoG levels performed on disk diffusion assays with FLC and adjuvants. c Effect of drug adjuvants and pathways inhibitors on the viability of cells growing inside the zone of inhibition. FLC disk diffusion assays of SC5314 without or with adjuvant were replica plated (after removal of the drug disk) onto casitone plates (without FLC or adjuvants) and incubated at 30 °C for 48 h. d, e FLC disk diffusion assays performed using a series of mutants carrying deletions in genes encoding the calcineurin subunit Cnb1, the calcineurin-responsive transcription factor Crz1, calcineurin regulators Rcn1 and Rcn2, MAP kinase Mkc1, vacuolar trafficking protein Vps21 (d), ergosterol biosynthesis regulator Upc2, and efflux pump regulators Tac1 and Mrr1 (e). These mutants as well as the rcn1 crz1 double mutant were analyzed by diskImageR, and RAD and FoG levels are shown relative to the isogenic parental strains (WT). All pictures in this figure are representative of two biological replicates, asterisks denote significant differences relative to corresponding parental strains. For all panels, n ≥ 2; ***P < 0.001; **P < 0.01; *P < 0.05, error bars denote standard deviations
Fig. 4 Adjuvant drugs significantly reduce FLC tolerance but not resistance and render FLC cidal. a Disk diffusion assays performed with 25 µg FLC on casitone plates supplemented with adjuvant drugs 20 µg/ml fluoxetine, 5 ng/ml aureobasidin A, 0.5 ng/ml rapamycin, 10 µg/ml fluphenazine, 12.5 ng/ml staurosporine, 0.25 µg/ml tunicamycin, Hsp90 inhibitors (0.5 µg/ml geldanamycin and 0.5 µg/ml radicicol), and calcineurin inhibitors (0.5 µg/ml FK506 and 0.4 µg/ml cyclosporine A) shown for strain SC5314. b RAD and FoG levels performed on disk diffusion assays with FLC and adjuvants. c Effect of drug adjuvants and pathways inhibitors on the viability of cells growing inside the zone of inhibition. FLC disk diffusion assays of SC5314 without or with adjuvant were replica plated (after removal of the drug disk) onto casitone plates (without FLC or adjuvants) and incubated at 30 °C for 48 h. d, e FLC disk diffusion assays performed using a series of mutants carrying deletions in genes encoding the calcineurin subunit Cnb1, the calcineurin-responsive transcription factor Crz1, calcineurin regulators Rcn1 and Rcn2, MAP kinase Mkc1, vacuolar trafficking protein Vps21 (d), ergosterol biosynthesis regulator Upc2, and efflux pump regulators Tac1 and Mrr1 (e). These mutants as well as the rcn1 crz1 double mutant were analyzed by diskImageR, and RAD and FoG levels are shown relative to the isogenic parental strains (WT). All pictures in this figure are representative of two biological replicates, asterisks denote significant differences relative to corresponding parental strains. For all panels, n ≥ 2; ***P < 0.001; **P < 0.01; *P < 0.05, error bars denote standard deviationsCC BY · PubMed Central
Fig. 5 Combination therapy partially rescues systemic infection of G. mellonella by high FoG C. albicans isolates. a G. mellonella larvae were injected with 3 × 105 yeast cells/larvae followed by a second injection with either PBS, FLC alone, or FLC and FNZ within 90 min of the first injection. b–d Survival curves of larvae infected with SC5314 (b), low FoG (c) and high FoG (d) isogenic derivatives. Each curve represents a group of 24 larvae (n = 24) which were monitored daily for survival for up to 14 days after infection. P values represent results of log-rank test comparing different treatment conditions with significance values as follows: ***P < 0.001; **P < 0.01; *P < 0.05; ns nonsignificant
Fig. 5 Combination therapy partially rescues systemic infection of G. mellonella by high FoG C. albicans isolates. a G. mellonella larvae were injected with 3 × 105 yeast cells/larvae followed by a second injection with either PBS, FLC alone, or FLC and FNZ within 90 min of the first injection. b–d Survival curves of larvae infected with SC5314 (b), low FoG (c) and high FoG (d) isogenic derivatives. Each curve represents a group of 24 larvae (n = 24) which were monitored daily for survival for up to 14 days after infection. P values represent results of log-rank test comparing different treatment conditions with significance values as follows: ***P < 0.001; **P < 0.01; *P < 0.05; ns nonsignificantCC BY · PubMed Central
Fig. 6 FoG and SMG levels differ between persistent and non-persistent isolates. a Candida albicans isolates from bloodstream infections were either efficiently cleared by a single course of FLC treatment (non-persistent) or persisted in the host despite multiple rounds of FLC therapy. b FoG and RAD levels for isolates SC5314, GC75, P78042, and P87 (reference isolates studied in Figs. 1–5), resistant (R, n = 1) isolate P6000231, the non-persistent isolates (NP, n = 7), and only the first patient isolate from each of the series of clinically persistent strains (P, n = 12). Asterisks indicate significant differences between persistent and non-persistent isolates (t test, ***P < 0.001). c Broth microdilution assays showing MIC and SMG levels at 24 and 48 h for the susceptible control strains, the non-persistent isolates as in b and for both the first and last isolates for each of the 12 clinically persistent series (S01–12). The final isolate of the S03 series of persistent strains had become FLC-resistant (MIC > 128 µg/ml, Supplementary Fig. 10a), and therefore the penultimate isolate, which remained susceptible, was used across analyses. Asterisks indicate significant differences between persistent and non-persistent isolates (t test, ***P < 0.001). For all panels isolates were tested in three or more biological replicates, error bars denote standard deviations
Fig. 6 FoG and SMG levels differ between persistent and non-persistent isolates. a Candida albicans isolates from bloodstream infections were either efficiently cleared by a single course of FLC treatment (non-persistent) or persisted in the host despite multiple rounds of FLC therapy. b FoG and RAD levels for isolates SC5314, GC75, P78042, and P87 (reference isolates studied in Figs. 1–5), resistant (R, n = 1) isolate P6000231, the non-persistent isolates (NP, n = 7), and only the first patient isolate from each of the series of clinically persistent strains (P, n = 12). Asterisks indicate significant differences between persistent and non-persistent isolates (t test, ***P < 0.001). c Broth microdilution assays showing MIC and SMG levels at 24 and 48 h for the susceptible control strains, the non-persistent isolates as in b and for both the first and last isolates for each of the 12 clinically persistent series (S01–12). The final isolate of the S03 series of persistent strains had become FLC-resistant (MIC > 128 µg/ml, Supplementary Fig. 10a), and therefore the penultimate isolate, which remained susceptible, was used across analyses. Asterisks indicate significant differences between persistent and non-persistent isolates (t test, ***P < 0.001). For all panels isolates were tested in three or more biological replicates, error bars denote standard deviationsCC BY · PubMed Central

Verification

Claims the paper makes

22 Valid · 2 Not valid · 6 Not checked · 136 Own results and interpretations

90 more claims · 4 with their cited sources checked

Create a free account to see all 166 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 52
  • Probably not a substantial claim. 33

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

38 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 133 references

Cited by

See all 270

Metadata

Authors
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J.
Affiliations
  • Tel Aviv University (IL)
  • Brown University (US)
  • University of California, San Francisco (US)
  • Universidade Federal de São Paulo (BR)
Corresponding author
Berman, Judith
Venue
Nature Communications
Published
2018-06-25
Volume
9
Issue
1
Pages
2470-2470
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2809480880
Cited by
270
References
133
Citations by year
2026: 51 · 2025: 39 · 2024: 32 · 2023: 36 · 2022: 26 · 2021: 30 · 2020: 27 · 2019: 19 · 2018: 9
FWCI
16.25
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health and Human Services (AI081704)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (17/02203-7)
  • National Institutes of Health (5r01ai081704-13, AI081704)
  • National Institute of Allergy and Infectious Diseases (R01-AI081704, R21AI139592)
  • FP7 Ideas: European Research Council (340087)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
  • Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Keywords
antifungal tolerance, Candida albicans, persistent candidemia, fluconazole, antifungal resistance, subpopulations, intracellular drug accumulation, invertebrate infection model, immunocompetent patient, treatment response prediction
MeSH terms
Antifungal Agents, Candida albicans, Drug Tolerance, Humans, Microbial Sensitivity Tests, Fluconazole, Drug Resistance, Fungal, Candidemia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. https://app.cochat.ai/papers/10.1038/s41467-018-04926-x
The paper
Rosenberg, A., Ene, I. V., Bibi, M., Zakin, S., Segal, E. S., Ziv, N., Dahan, A. M., Colombo, A. L., Bennett, R. J., & Berman, J. (2018). Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia. Nature Communications. https://doi.org/10.1038/s41467-018-04926-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.